Issuer Direct Corporation
Total Revenue of $5.5 million Led by ACCESSWIRE Revenue Which Increased Over 30%, Net Income Increased 30% and EBITDA Increased 16% to $1.6 million or 30% of Revenue
RALEIGH, NC / ACCESSWIRE / November 4, 2021 / Issuer Direct Corporation (NYSE American:ISDR) (the "Company"), an industry-leading communications and compliance company, today reported its operating results for the three and nine months ended September 30, 2021.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Brian Balbirnie, CEO of Issuer Direct, commented, "The third quarter helped support what has been a record year in terms of revenue for us, led by our ACCESSWIRE brand, which increased over 30% from the third quarter of the prior year. We continued to invest in our platform and expand our sales organization, which contributed to higher operating costs during the quarter, however, we believe this investment will provide long-term benefits in further customer growth and gross margin improvement."
Mr. Balbirnie continued, "These initiatives are important and will continue to be a focus for the remainder of the year. As a result of our product development, we launched a comprehensive newsroom subscription offering mid-way through the third quarter. We are seeing early interest in our newsroom product, something we expect will continue for the year and contribute to our expected growth next year. Our sales organization continues to grow its pipeline of platform subscriptions and first-time customers subscribing to ACCESSWIRE are producing higher year over year revenues, an indicator that our digital marketing strategy is working."
Mr. Balbirnie concluded, "Looking ahead, we remain focused on continuing to increase both our customer counts and revenues. We believe this will be led by ACCESSWIRE, our newsroom product and our entire communications platform, a combination that we believe will result in higher average revenues per user. Strategically, we continue to focus on products and businesses we believe we need to acquire to further expand our platform, customer and geographic reach."
Third Quarter 2021 Highlights:
- Revenue - Total revenue was $5,465,000, a 12% increase from $4,882,000 in Q3 2020 and a 4% decrease from $5,720,000 in Q2 2021. Communications revenue increased 10% from Q3 2020 and 5% from Q2 2021. The increase in Communications revenue is primarily due to the combination of increased revenue from our ACCESSWIRE product due to increased volume and pricing and an increase in revenue from subscriptions of Platform id. As compared to Q3 2020, these increases were partially offset by a decline in revenue from our events and webcasting business due to lower demand during Q3 2021. Communications revenue was 67% of total revenue for Q3 2021, compared to 69% for Q3 2020. Revenue from our Compliance business increased 17% from Q3 2020 and decreased 20% from Q2 2021. The increase compared to Q3 2020 was due to an increase in revenue from our print and proxy fulfillment services as well as our stock transfer services due to increased market activity. The decrease from Q2 2021 was due to seasonality of print and proxy fulfillment services as most annual meetings occur during the second quarter.
- Gross Margin - Gross margin for Q3 2021 was $4,110,000, or 75% of revenue, compared to $3,495,000, or 72% of revenue, during Q3 2020 and $4,240,000, or 74%, in Q2 2021. Communications gross margin was 78%, an increase from 74% in Q3 2020 and 75% in Q2 2021 due to increased scale in our ACCESSWIRE product.
- Operating Income - Operating income was $977,000 for Q3 2021, compared to $1,076,000 during Q3 2020. The decrease in operating income is due to higher operating expenses, primarily due to continued investment and expansion of our headcount, particularly in our sales and marketing and product development teams as well as higher professional fees related to ongoing projects.
- Net Income - On a GAAP basis, net income was $1,024,000, or $0.27 per diluted share, during Q3 2021, compared to $789,000, or $0.21 per diluted share, during Q3 2020. During Q3 2021, we recorded a one-time benefit of $366,000 related to employee retention credits related to the CARES Act.
- Operating Cash Flows - Cash flows from operations for Q3 2021 were $1,238,000 compared to $1,321,000 in Q3 2020.
- Non-GAAP Measures - Q3 2021 EBITDA was $1,632,000, or 30% of revenue, compared to $1,401,000, or 29% of revenue, during Q3 2020. Non-GAAP net income for Q3 2021 was $906,000, or $0.24 per diluted share, compared to $963,000, or $0.26 per diluted share, during Q3 2020.
Year-to-date Q3 2021 Highlights:
- Revenue - Total revenue was $16,165,000, a 17% increase from $13,782,000 during the first nine months of 2020. Communications revenue increased 18% during the first nine months of 2021 compared to the same period of the prior year. The increase in Communications revenue was primarily due to the combination of increased revenue from our ACCESSWIRE product and an increase in revenue from subscriptions of Platform id., partially offset by a decrease in revenue from our events and webcasting business. Communications revenue remained 64% of total revenue for both the first nine months of 2021 and 2020. Revenue from our Compliance business increased 16% during the first nine months of 2021 compared to the same period of 2020. The increase was due to an increase in revenue from our print and proxy fulfillment services as well as our stock transfer services due to increased market activity.
- Gross Margin - Gross margin for the first nine months of 2021 was $11,936,000, or 74% of revenue, compared to $9,780,000, or 71% of revenue, during the first nine months of 2020. Communications gross margin was 75% during the first nine months of 2021, up 2% from the first nine months of 2020 due to increased scale in our ACCESSWIRE product.
- Operating Income - Operating income was $3,045,000 for the first nine months of 2021, compared to $2,325,000 during the same period of 2020. The increase in operating income is due to an increase in gross margin partially offset by higher operating expenses, primarily due to continued investment and expansion of our headcount, including our sales and marketing and product development teams as well as higher professional fees related to ongoing projects.
- Net Income - On a GAAP basis, net income was $2,675,000, or $0.70 per diluted share, during the first nine months of 2021, compared to $1,787,000, or $0.47 per diluted share, during the first nine months of 2020. During the first nine months of 2021, we recorded a one-time benefit of $366,000 related to employee retention credits related to the CARES Act.
- Operating Cash Flows - Cash flows from operations for the first nine months of 2021 were $3,319,000 compared to $3,400,000 during the same period of 2020.
- Non-GAAP Measures - EBITDA for the first nine months of 2021 was $4,265,000, or 26% of revenue, compared to $3,377,000, or 25% of revenue, during the same period of 2020. Non-GAAP net income for the first nine months of 2021 was $2,778,000, or $0.73 per diluted share, compared to $2,334,000, or $0.62 per diluted share, during the same period of 2020.
- Stock Repurchase Plan - The Company completed its $2,000,000 repurchase program originally announced on August 7, 2019 and increased on March 16, 2020 by repurchasing the remaining balance under the plan of $452,000 or 19,777 shares of its common shares during the first quarter of 2021.
Key Performance Indicators:
- During the quarter, the Company worked with 1,683 publicly traded customers, compared to 1,475 during the same period last year.
- During the quarter, the Company worked with 1,815 privately held customers compared to 1,597 during the same period last year.
- During the quarter we signed 40 new Platform id. subscriptions to new or existing customers with a total annual contract value of $306,000.
- Total Platform id. subscriptions as of September 30, 2021 were 418, with an annual contract value of $3,499,000, compared to 341 subscriptions with an annual contract value of $2,677,000 as of December 31, 2020.
Non-GAAP Information
Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, other unusual items, tax impact of adjustments and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
($ in ‘000's, except per share amounts)
CALCULATION OF EBITDA
| Three Months ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Amount | Amount | |||||||
Net income: | $ | 1,024 | $ | 789 | ||||
Adjustments: | ||||||||
Depreciation and amortization | 289 | 325 | ||||||
Interest income | - | 4 | ||||||
Income tax expense | 319 | 283 | ||||||
EBITDA: | $ | 1,632 | $ | 1,401 | ||||
| Nine Months ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Amount | Amount | |||||||
Net income: | $ | 2,675 | $ | 1,787 | ||||
Adjustments: | ||||||||
Depreciation and amortization | 854 | 1,052 | ||||||
Interest income | (2 | ) | (55 | ) | ||||
Income tax expense | 738 | 593 | ||||||
EBITDA: | $ | 4,265 | $ | 3,377 | ||||
CALCULATION OF NON-GAAP NET INCOME
| Three Months ended September 30, | ||||||||||||||||
| 2021 | 2020 | |||||||||||||||
| Amount | Per diluted share | Amount | Per diluted share | |||||||||||||
Net income: | $ | 1,024 | $ | 0.27 | $ | 789 | $ | 0.21 | ||||||||
Adjustments: | ||||||||||||||||
Amortization of intangible assets (1) | 116 | 0.03 | 148 | 0.04 | ||||||||||||
Stock-based compensation (2) | 100 | 0.03 | 72 | 0.02 | ||||||||||||
Other unusual items (3) | (366 | ) | (0.10 | ) | - | - | ||||||||||
Tax impact of adjustments (4) | 32 | 0.01 | (46 | ) | (0.01 | ) | ||||||||||
Non-GAAP net income: | $ | 906 | $ | 0.24 | $ | 963 | $ | 0.26 | ||||||||
| Nine Months ended September 30, | ||||||||||||||||
| 2021 | 2020 | |||||||||||||||
| Amount | Per diluted share | Amount | Per diluted share | |||||||||||||
Net income: | $ | 2,675 | $ | 0.70 | $ | 1,787 | $ | 0.48 | ||||||||
Adjustments: | ||||||||||||||||
Amortization of intangible assets (1) | 349 | 0.09 | 492 | 0.13 | ||||||||||||
Stock-based compensation (2) | 232 | 0.06 | 201 | 0.05 | ||||||||||||
Other unusual items (3) | (366 | ) | (0.10 | ) | - | - | ||||||||||
Tax impact of adjustments (4) | (45 | ) | (0.01 | ) | (146 | ) | (0.04 | ) | ||||||||
Impact of discrete items impacting income tax expense (5) | (67 | ) | (0.01 | ) | - | - | ||||||||||
Non-GAAP net income: | $ | 2,778 | $ | 0.73 | $ | 2,334 | $ | 0.62 | ||||||||
1) The adjustments represent the amortization of intangible assets related to acquired assets and companies.
2) The adjustments represent stock-based compensation expense related to awards of stock options, restricted stock units or common stock in exchange for services. Although the Company expects to continue to award stock in exchange for services, the amount of stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects.
3) This adjustment gives effect to the benefit recorded during the three and nine months ended September 30, 2021, associated with employee retention credits related to the CARES act.
4) This adjustment gives effect to the tax impact of all non-GAAP adjustments at the current Federal rate of 21%.
5) This adjustment eliminates discrete items impacting income tax expense. For the nine months ended September 30, 2021, the discrete item relates to an excess stock-based compensation benefit recognized in income tax during the period.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: November 4, 2021
Time: 4:30 PM ET
Toll-free: 833-492-0063
International: 973-528-0130
Live Webcast: https://www.webcaster4.com/Webcast/Page/842/43396
Conference Call Replay Information
Toll-free: 877-481-4010
International: 919-882-2331
Replay ID: 43396
Web replay: http://www.issuerdirect.com/earnings-calls-and-scripts/
About Issuer Direct Corporation
Issuer Direct ® is an industry-leading communications and compliance company focusing on the needs of corporate issuers. Issuer Direct's principal platform, Platform id. ™, empowers users by thoughtfully integrating the most relevant tools, technologies, and services, thus eliminating the complexity associated with producing and distributing financial and business communications. Headquartered in Raleigh, NC, Issuer Direct serves thousands of public and private companies globally. For more information, please visit www.issuerdirect.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons including the impact of the coronavirus pandemic. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2020, including but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/ .
For Further Information:
Issuer Direct Corporation
Brian R. Balbirnie
(919)-481-4000
brian.balbirnie@issuerdirect.com
Hayden IR
Brett Maas
(646)-536-7331
brett@haydenir.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
ISSUER DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
ASSETS | (unaudited) | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 22,415 | $ | 19,556 | ||||
Accounts receivable (net of allowance for doubtful accounts of $702 and $657, respectively) | 3,037 | 2,514 | ||||||
Income tax receivable | 28 | - | ||||||
Other current assets | 761 | 298 | ||||||
Total current assets | 26,241 | 22,368 | ||||||
Capitalized software (net of accumulated amortization of $3,159 and $2,761, respectively) | 343 | 526 | ||||||
Fixed assets (net of accumulated depreciation of $419 and $312, respectively) | 737 | 795 | ||||||
Right-of-use asset - leases | 1,607 | 1,830 | ||||||
Other long-term assets | 93 | 88 | ||||||
Goodwill | 6,376 | 6,376 | ||||||
Intangible assets (net of accumulated amortization of $5,895 and $5,546, respectively) | 2,557 | 2,906 | ||||||
Total assets | $ | 37,954 | $ | 34,889 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 667 | $ | 304 | ||||
Accrued expenses | 1,654 | 1,805 | ||||||
Income taxes payable | 61 | 258 | ||||||
Deferred revenue | 2,696 | 2,212 | ||||||
Total current liabilities | 5,078 | 4,579 | ||||||
Deferred income tax liability | 262 | 197 | ||||||
Lease liabilities - long-term | 1,738 | 1,971 | ||||||
Total liabilities | 7,078 | 6,747 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. | - | - | ||||||
Common stock $0.001 par value, 20,000,000 shares authorized, 3,791,038 and 3,770,752 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. | 4 | 4 | ||||||
Additional paid-in capital | 22,268 | 22,214 | ||||||
Other accumulated comprehensive loss | (14 | ) | (19 | ) | ||||
Retained earnings | 8,618 | 5,943 | ||||||
Total stockholders' equity | 30,876 | 28,142 | ||||||
Total liabilities and stockholders' equity | $ | 37,954 | $ | 34,889 | ||||
ISSUER DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except share and per share amounts)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenues | $ | 5,465 | $ | 4,882 | $ | 16,165 | $ | 13,782 | ||||||||
Cost of revenues | 1,355 | 1,387 | 4,229 | 4,002 | ||||||||||||
Gross profit | 4,110 | 3,495 | 11,936 | 9,780 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||
General and administrative | 1,258 | 1,052 | 3,923 | 3,465 | ||||||||||||
Sales and marketing expenses | 1,349 | 973 | 3,633 | 2,819 | ||||||||||||
Product development | 373 | 212 | 878 | 571 | ||||||||||||
Depreciation and amortization | 153 | 182 | 457 | 600 | ||||||||||||
Total operating costs and expenses | 3,133 | 2,419 | 8,891 | 7,455 | ||||||||||||
Operating income | 977 | 1,076 | 3,045 | 2,325 | ||||||||||||
Other income, net | 366 | (4 | ) | 368 | 55 | |||||||||||
Income before taxes | 1,343 | 1,072 | 3,413 | 2,380 | ||||||||||||
Income tax expense | 319 | 283 | 738 | 593 | ||||||||||||
Net income | $ | 1,024 | $ | 789 | $ | 2,675 | $ | 1,787 | ||||||||
Income per share - basic | $ | 0.27 | $ | 0.21 | $ | 0.71 | $ | 0.48 | ||||||||
Income per share - fully diluted | $ | 0.27 | $ | 0.21 | $ | 0.70 | $ | 0.47 | ||||||||
Weighted average number of common shares outstanding - basic | 3,788 | 3,740 | 3,776 | 3,754 | ||||||||||||
Weighted average number of common shares outstanding - fully diluted | 3,821 | 3,768 | 3,818 | 3,778 | ||||||||||||
ISSUER DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
| For the Nine Months Ended | ||||||||
| September 30, | September 30, | |||||||
| 2021 | 2020 | |||||||
Cash flows from operating activities: | ||||||||
Net income | $ | 2,675 | $ | 1,787 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 854 | 1,052 | ||||||
Bad debt expense | 236 | 242 | ||||||
Deferred income taxes | (14 | ) | (27 | ) | ||||
Non-cash interest expense | - | 19 | ||||||
Stock-based compensation expense | 232 | 201 | ||||||
Changes in operating assets and liabilities: | ||||||||
Decrease (increase) in accounts receivable | (767 | ) | (634 | ) | ||||
Decrease (increase) in other assets | (273 | ) | 191 | |||||
Increase (decrease) in accounts payable | 365 | 89 | ||||||
Increase (decrease) in accrued expenses | (489 | ) | 195 | |||||
Increase (decrease) in deferred revenue | 500 | 285 | ||||||
Net cash provided by operating activities | 3,319 | 3,400 | ||||||
Cash flows from investing activities: | ||||||||
Capitalized software | (215 | ) | - | |||||
Purchase of fixed assets | (49 | ) | (15 | ) | ||||
Net cash used in investing activities | (264 | ) | (15 | ) | ||||
Cash flows from financing activities: | ||||||||
Exercise of stock options | 274 | 66 | ||||||
Payment for stock repurchase and retirement | (452 | ) | (785 | ) | ||||
Net cash used in financing activities | (178 | ) | (719 | ) | ||||
Net change in cash and cash equivalents | 2,877 | 2,666 | ||||||
Cash - beginning | 19,556 | 15,766 | ||||||
Currency translation adjustment | (18 | ) | (3 | ) | ||||
Cash and cash equivalents - ending | $ | 22,415 | $ | 18,429 | ||||
Supplemental disclosures: | ||||||||
Cash paid for income taxes | $ | 893 | $ | 323 | ||||
SOURCE: Issuer Direct Corporation
View source version on accesswire.com:
https://www.accesswire.com/670864/Issuer-Direct-Reports-Third-Quarter-2021-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
